The association of osteopontin and LMX1A expression with World Health Organization grade in meningiomas and gliomas

Histopathology

Volumn 61, Issue 5, 2012, Pages 844-856

  Tsai, Wen Chiuan ^a   Lee, Herng Sheng ^a   Lin, Chih Kung ^a   Chen, Ann ^a   Nieh, Shin ^a   Ma, Hsin I ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Glioma; Immunostaining scores; LIM homeobo x transcription factor 1 alpha; Meningioma; Osteopontin

Indexed keywords

LIM HOMEOBOX TRANSCRIPTION FACTOR 1 ALPHA; OSTEOPONTIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; GLIOMA; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MENINGIOMA; NEUROEPITHELIOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; WORLD HEALTH ORGANIZATION;

BRAIN NEOPLASMS; DISEASE PROGRESSION; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; LIM-HOMEODOMAIN PROTEINS; MENINGEAL NEOPLASMS; MENINGIOMA; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEUROCYTOMA; OSTEOPONTIN; TRANSCRIPTION FACTORS; WORLD HEALTH ORGANIZATION;

EID: 84868140494     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04277.x     Document Type: Article

References (50)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J. Clin. 2003; 53; 5-26.
2. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro. Oncol. 2002; 4; 278-299.
3. Louis DN, Ohgaki H, Weistler OD, Cavenee WK. World Health Organization classification of tumours of the central nervous system. Lyon: IARC Press, 2007; 8-172.
4. Bellail AC, Hunter SB, Brat DJ, Tan C, Van Meir EG. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int. J. Biochem. Cell Biol. 2004; 36; 1046-1069.
5. Kujas M. Meningioma. Curr. Opin. Neurol. 1993; 6; 882-887.
6. Burger PC, Scheithauer BW, Vogel FS. Surgical pathology of the central nervous system and its coverings. London: Churchill Livingstone, 1994.
7. Kepes JJ. Meningiomas. Biology, pathology, and differential diagnosis. New York: Masson Publishing, 1982.
8. Lantos PL, VandenBerg SR, Kleihues P. Tumors of the nervous system. In Graham DI, Lantos PL eds. Greenfield's neuropatholog. London: Arnold, 1996; 583-879.
9. Jääskeläinen J. Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg. Neurol. 1986; 26; 461-469.
10. Perry A, Gutmann DH, Reifenberger G. Molecular pathogenesis of meningiomas. J. Neurooncol. 2004; 70; 183-202.
11. Vankalakunti M, Vasishta RK, Das Radotra B, Khosla VK. MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas. Neuropathology 2007; 27; 407-412.
12. Denhardt DT, Noda M. Osteopontin expression and function: role in bone remodeling. J. Cell. Biochem. Suppl. 1998; 30; 92-102.
13. Sodek J, Ganss B, McKee MD. Osteopontin. Crit. Rev. Oral Biol. Med. 2000; 11; 279-303.
14. Liaw L, Skinner MP, Raines EW et al. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J. Clin. Invest. 1995; 95; 713-724.
15. Xuan JW, Hota C, Shigeyama Y, D'Errico JA, Somerman MJ, Chambers AF. Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions. J. Cell. Biochem. 1995; 57; 680-690.
16. Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF, Giachelli CM. NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. J. Cell Biol. 1998; 141; 1083-1093.
17. Patarca R, Saavedra RA, Cantor H. Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. Crit. Rev. Immunol. 1993; 13; 225-246.
18. Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 1979; 16; 885-893.
19. Senger DR, Perruzzi CA. Secreted phosphoprotein markers for neoplastic transformation of human epithelial and fibroblastic cells. Cancer Res. 1985; 45; 5818-5823.
20. Pan HW, Ou YH, Peng SY et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 2003; 98; 119-127.
21. Tuck AB, Chambers AF. The role of osteopontin in breast cancer: clinical and experimental studies. J. Mammary Gland Biol. Neoplasia 2001; 6; 419-429.
22. Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF, Casson AG. Osteopontin expression in lung cancer. Lung Cancer 1996; 15; 311-323.
23. Thalmann GN, Sikes RA, Devoll RE et al. Osteopontin: possible role in prostate cancer progression. Clin. Cancer Res. 1999; 5; 2271-2277.
24. Higashiyama M, Ito T, Tanaka E, Shimada Y. Prognostic significance of osteopontin expression in human gastric carcinoma. Ann. Surg. Oncol. 2007; 14; 3419-3427.
25. Wang HH, Wang XW, Tang CE. Osteopontin expression in nasopharyngeal carcinoma: its relevance to the clinical stage of the disease. J. Cancer Res. Ther. 2011; 7; 138-142.
26. Lu JG, Li Y, Li L, Kan X. Overexpression of osteopontin and integrin αv in laryngeal and hypopharyngeal carcinomas associated with differentiation and metastasis. J. Cancer Res. Clin. Oncol. 2011; 137; 1613-1618.
27. Matušan-Ilijaš K, Damante G, Fabbro D et al. Osteopontin expression correlates with nuclear factor-κB activation and apoptosis downregulation in clear cell renal cell carcinoma. Pathol. Res. Pract. 2011; 207; 104-110.
28. Maier T, Laubender RP, Sturm RA et al. Osteopontin expression in plasma of melanoma patients and in melanocytic tumours. J. Eur. Acad. Dermatol. Venereol. 2011. Doi:10.1111/j.1468-3083.2011.04210.x.
29. Toy H, Yavas O, Eren O, Genc M, Yavas C. Correlation between osteopontin protein expression and histological grade of astrocytomas. Pathol. Oncol. Res. 2009; 15; 203-207.
30. Tseng KY, Chung MH, Sytwu HK et al. Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas. J. Neurooncol. 2010; 100; 217-223.
31. Dong W, Feng L, Xie Y, Zhang H, Wu Y. Hypermethylation-mediated reduction of LMX1A expression in gastric cancer. Cancer Sci. 2011; 102; 361-366.
32. Liu CY, Chao TK, Su PH et al. Characterization of LMX-1A as a metastasis suppressor in cervical cancer. J. Pathol. 2009; 219; 222-231.
33. Su HY, Lai HC, Lin YW, Chou YC, Liu CY, Yu MH. An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int. J. Cancer 2009; 124; 387-393.
34. Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM. Epidemiology of intracranial meningioma. Neurosurgery 2005; 57; 1088-1095.
35. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC. 'Malignancy' in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 1999; 85; 2046-2056.
36. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. Meningioma grading: an analysis of histologic parameters. Am. J. Surg. Pathol. 1997; 21; 1455-1465.
37. Gu J, Liu Y, Kyritsis AP, Bondy ML. Molecular epidemiology of primary brain tumors. Neurotherapeutics 2009; 6; 427-435.
38. Pinto GR, Yoshioka FK, Silva RL et al. Prognostic value of TP53 Pro47Ser and Arg72Pro single nucleotide polymorphisms and the susceptibility to gliomas in individuals from Southeast Brazil. Genet. Mol. Res. 2008; 7; 207-216.
39. Rajaraman P, Wang SS, Rothman N et al. Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol. Biomarkers Prev. 2007; 16; 1655-1661.
40. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol. 1993; 3; 255-268.
41. Gagner JP, Law M, Fischer I, Newcomb EW, Zagzag D. Angiogenesis in gliomas: imaging and experimental therapeutics. Brain Pathol. 2005; 15; 342-363.
42. Nelson SJ, Cha S. Imaging glioblastoma multiforme. Cancer J. 2003; 9; 134-145.
43. Cha S. Update on brain tumor imaging. Curr. Neurol. Neurosci. Rep. 2005; 5; 169-177.
44. Matusan-Ilijas K, Behrem S, Jonjic N, Zarkovic K, Lucin K. Osteopontin expression correlates with angiogenesis and survival in malignant astrocytoma. Pathol. Oncol. Res. 2008; 14; 293-298.
45. Lang FF, Miller DC, Koslow M, Newcomb EW. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J. Neurosurg. 1994; 81; 427-436.
46. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol. 1993; 3; 19-26.
47. Cenacchi G, Giangaspero F. Emerging tumor entities and variants of CNS neoplasms. J. Neuropathol. Exp. Neurol. 2004; 63; 185-192.
48. Jan HJ, Lee CC, Shih YL et al. Osteopontin regulates human glioma cell invasiveness and tumor growth in mice. Neuro. Oncol. 2010; 12; 58-70.
49. Chen X, Cao X, Dong W, Luo S, Suo Z, Jin Y. Expression of TIP30 tumor suppressor gene is down-regulated in human colorectal carcinoma. Dig. Dis. Sci. 2010; 55; 2219-2226.
50. Toyota M, Suzuki H, Sasaki Y et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 2008; 68; 4123-4132.